- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Sentynl Therapeutics has received acceptance and a six-month priority review for its New Drug Application (NDA) for CUTX-101, a potential treatment for the rare and severe Menkes disease, with a target action date set for June 30, 2025. This therapy could be a landmark approval, as there are currently no FDA-approved treatments for this pediatric disorder caused by ATP7A gene mutations. Clinical trials indicate that early treatment with CUTX-101 significantly improves survival rates, with median overall survival of 177.1 months compared to just 16.1 months in untreated patients. The company emphasizes its commitment to addressing unmet medical needs and improving quality of life for affected families. The implications for investors are noteworthy, as the successful approval of CUTX-101 could position Sentynl as a key player in the rare disease market, presenting a 'positive outlook' for growth opportunities ahead.